HOME >> BIOLOGY >> NEWS
Tramiprosate (Alzhemed) preclinical results published in Neurobiology of Aging

Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that Neurobiology of Aging, one of the world's leading peer-reviewed medical journals in the fields of gerontology and neuroscience, has published an online version of a publication on the preclinical development of tramiprosate (3-amino-1-propanesulfonic acid; Alzhemed), including efficacy results in a mouse model of brain amyloidosis. Tramiprosate (Alzhemed) represents a potential new class of therapeutic agent and is Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The results presented in this paper include the amyloid binding and neuroprotective characteristics of tramiprosate (Alzhemed) and provide evidence for the potential disease-modifying effect of this product candidate to slow or arrest the progression of AD.

While the paper issue of the publication will be available in a future issue of Neurobiology of Aging, an electronic version of the article entitled "Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis" is already accessible online, and can be found at http://www.sciencedirect.com by searching for "tramiprosate".

Findings about tramiprosate (Alzhemed) include:

  • Tramiprosate (Alzhemed) binds preferentially to soluble Aβ peptide and maintains Aβ in a non-fibrillar form.
  • Tramiprosate (Alzhemed) decreases by 38% (p-value < 0.01) Aβ42-induced cell death in primary rat neuronal cell cultures.
  • Tramiprosate (Alzhemed) treatment in a transgenic mouse model of brain amyloidosis resulted in a dose-dependent reduction of over 60% of Aβ levels in plasma. There were significant decreases in brain levels of both soluble Aβ40 (30%; p-value of 0.014) and insoluble Aβ40 (31%; p-value of 0.035). Corresponding decreases of 25% (p-value of 0.033) and 22% (p-value of 0.029) were observed for the soluble a
    '"/>


Contact: Lise Hébert, PhD
lhebert@neurochem.com
450-680-4570
Neurochem, Inc.
30-May-2006


Page: 1 2 3

Related biology news :

1. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
2. Promising preclinical results with live attenuated H5N1 vaccines
3. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
4. Cytori demonstrates adipose stem cells improve cardiac function in preclinical heart attack model
5. Cooperative science program yields results
6. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
7. Smelling for first time results from knowing abnormalities in congenital loss of smell
8. BDSI announces positive phase III clinical trial results
9. Scientists meet to review Envisat results after 5 years of operations
10. Environment and exercise may affect research results, UA study shows
11. Preliminary results of largest scan of autism DNA information

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/30/2020)... Ontario (PRWEB) , ... January 30, 2020 , ... ... with an eye on the Canadian market, is pleased to announce that the company ... of growth since the company launched in 2017. , “We are so thrilled ...
(Date:1/29/2020)... ... January 29, 2020 , ... ... vitro toxicology testing solutions, has announced a record earnings year for 2019. With ... showed more than a twenty percent increase in revenue and a thirty percent ...
(Date:1/28/2020)... CAMBRIDGE, Mass. (PRWEB) , ... January 28, 2020 ... ... problems for life sciences companies and government agencies, announced that the firm has ... in the country. Tunnell’s Cambridge office will be in the Cambridge Innovation Center ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... Genedata, ... the release of Genedata Expressionist ® 13.5 at the 2020 WCBP ... Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their ...
(Date:1/24/2020)... ... January 24, 2020 , ... The ... in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades ... the world. And as Slone Partners celebrates its 20th anniversary this ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... precision of Genome editing. The partners have agreed to co-develop and market a ... research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop ...
(Date:1/8/2020)... ... January 08, 2020 , ... Anomet Products ... specific properties for use in harsh environments inside or outside of the human ... three metals or alloys to achieve specific properties such as corrosion-resistance, biocompatibility, or ...
Breaking Biology Technology:
Cached News: